MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Insmed Incorporated ROCE Ratio 2011-2026 | INSM
Annual ROCE Ratio Insmed Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -168.72 | -307.75 | 213.79 | -519.97 | -91.38 | -96.14 | -35.8 | -58.56 | -45.26 | -82.58 | -35.15 | -41.36 | -34.38 | -30.79 | -26.4 | -4.2 | -7.0 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 213.79 | -519.97 | -80.68 |
Quarterly ROCE Ratio Insmed Incorporated
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -335.74 | -358.14 | -1063.68 | -1007.34 | -757.1 | -706.07 | -510.69 | 565.36 | 534.06 | 960.3 | 709.64 | 483.48 | 151.68 | 131.15 | -311.76 | -153.71 | -78.78 | -99.16 | -98.25 | -103.45 | -61.87 | -79.86 | -81.07 | -85.21 | -89.9 | -114.03 | -132.77 | -144.0 | -147.57 | -123.55 | -95.43 | -72.49 | -52.32 | -77.63 | -89.46 | -100.8 | -112.25 | -79.3 | -64.95 | -50.53 | -37.69 | -39.62 | -42.49 | -45.77 | -46.91 | -45.41 | -44.59 | -38.11 | -38.39 | -40.61 | -36.59 | -39.08 | -35.11 | -28.61 | -46.91 | -46.45 | -45.97 | -26.04 | -7.8 | -5.52 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 960.3 | -1063.68 | -77.35 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
-27.78 | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-35.64 | $ 7.47 | -4.6 % | $ 205 M |  Israel |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-41.41 | - | 0.74 % | $ 768 M | Israel |
 |
Eton Pharmaceuticals
ETON
|
-3.23 | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | USA |
 |
Exelixis
EXEL
|
40.35 | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
-140.8 | $ 2.41 | 4.78 % | $ 67.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-71.74 | - | -18.52 % | $ 27.3 M | Britain |
|
Forte Biosciences
FBRX
|
-115.85 | $ 23.11 | -3.55 % | $ 299 M | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.63 | 2.52 % | $ 434 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
-7.08 | $ 89.55 | -2.65 % | $ 21.6 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
15.7 | $ 2.17 | -7.66 % | $ 139 M | USA |
 |
Celyad Oncology SA
CYAD
|
-439.8 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Gilead Sciences
GILD
|
44.14 | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.36 | -3.72 % | $ 5.53 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-0.65 | $ 0.72 | -1.58 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.12 | - | $ 649 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Genmab A/S
GMAB
|
31.74 | $ 26.54 | -1.34 % | $ 1.72 B |  Danmark |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |